Journal
THORAX
Volume 74, Issue 10, Pages 965-976Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/thoraxjnl-2019-213037
Keywords
lung cancer; cystic fibrosis; pneumonia; asthma; copd pharmacology
Categories
Funding
- Science Foundation Ireland (SFI)
- Health Research Board (HRB)
- Science Foundation Ireland (SFI) under the AMBER Centre Directors Fund project [12565]
Ask authors/readers for more resources
Nanomedicine is a multidisciplinary research field with an integration of traditional sciences such as chemistry, physics, biology and materials science. The application of nanomedicine for lung diseases as a relatively new area of interdisciplinary science has grown rapidly over the last 10 years. Promising research outcomes suggest that nanomedicine will revolutionise the practice of medicine, through the development of new approaches in therapeutic agent delivery, vaccine development and nanotechnology-based medical detections. Nano-based approaches in the diagnosis and treatment of lung diseases will, in the not too distant future, change the way we practise medicine. This review will focus on the current trends and developments in the clinical translation of nanomedicine for lung diseases, such as in the areas of lung cancer, cystic fibrosis, asthma, bacterial infections and COPD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available